SGMTSagimet Biosciences - Series A Common StockSGMT info
$3.41info0.89%24h
Global rank23029
Market cap$72.89M
Change 7d13.29%
YTD Performance-36.26%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Sagimet Biosciences - Series A Common Stock (SGMT) Stock Overview

    Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

    SGMT Stock Information

    Symbol
    SGMT
    Address
    155 Bovet RoadSan Mateo, CA 94402United States
    Founded
    -
    Trading hours
    -
    Website
    https://sagimet.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    650-561-8600

    Sagimet Biosciences - Series A Common Stock (SGMT) Price Chart

    -
    Value:-

    Sagimet Biosciences - Series A Common Stock Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $3.41
    N/A
    Market Cap
    $72.89M
    N/A
    Shares Outstanding
    21.38M
    N/A
    Employees
    9.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org